Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy

References

• Anwanwan D, Singh SK, Singh S, et al. (2020). Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer 1873:188314.
   PubMed Web of Science ®Google Scholar
• Cartwright T, Perkins ND, L Wilson C. (2016). NFKB1: a suppressor of inflammation, ageing and cancer. Febs J 283:1812–22.
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, van Hoogevest P, Storm G. (2020). The role of liposomes in clinical nanomedicine development. What now? Now what? J Control Release 318:256–63.
   PubMed Web of Science ®Google Scholar
• Daher S, Massarwa M, Benson AA, Khoury T. (2018). Current and future treatment of hepatocellular carcinoma: an updated comprehensive review. J Clin Transl Hepatol 6:69–78.
   PubMed Web of Science ®Google Scholar
• Elnaggar MH, Abushouk AI, Hassan AHE, et al. (2021). Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. Semin Cancer Biol 69:91–9.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–53.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. (2018). Hepatocellular carcinoma. Lancet 391:1301–14.
   PubMed Web of Science ®Google Scholar
• Gubernator J. (2011). Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv 8:565–80.
   PubMed Web of Science ®Google Scholar
• Hou W, Liu B, Xu H. (2019). Triptolide: Medicinal chemistry, chemical biology and clinical progress. Eur J Med Chem 176:378–92.
   PubMed Web of Science ®Google Scholar
• Hou ZY, Tong XP, Peng YB, et al. (2018). Broad targeting of triptolide to resistance and sensitization for cancer therapy. Biomed Pharmacother 104:771–80.
   PubMed Web of Science ®Google Scholar
• Jao HY, Yu FS, Yu CS, et al. (2016). Suppression of the migration and invasion is mediated by triptolide in B16F10 mouse melanoma cells through the NF-kappaB-dependent pathway. Environ Toxicol 31:1974–84.
   PubMed Web of Science ®Google Scholar
• Jiang L, Gu Y, Du Y, et al. (2021). Engineering exosomes endowed with targeted delivery of triptolide for malignant melanoma therapy. ACS Appl Mater Interfaces 13:42411–28.
   PubMed Web of Science ®Google Scholar
• Jono H, Lim JH, Chen LF, et al. (2004). NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 279:36171–4.
   PubMed Web of Science ®Google Scholar
• Kooijmans SAA, Vader P, Schiffelers RM. (2017). Tumour-bound RNA-laden exosomes. Nat Biomed Eng 1:634–6. Aug
   PubMed Web of Science ®Google Scholar
• Krosch TC, Sangwan V, Banerjee S, et al. (2013). Triptolide-mediated cell death in neuroblastoma occurs by both apoptosis and autophagy pathways and results in inhibition of nuclear factor-kappa B activity. Am J Surg 205:387–96.
   PubMed Web of Science ®Google Scholar
• Kupchan SM, Court WA, Dailey RG, Jr, et al. (1972). Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 94:7194–5.
   PubMed Web of Science ®Google Scholar
• Leggio L, Arrabito G, Ferrara V, et al. (2020). Mastering the tools: natural versus artificial vesicles in nanomedicine. Adv Healthc Mater 9:e2000731.
   PubMed Web of Science ®Google Scholar
• Lener T, Gimona M, Aigner L, et al. (2015). Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles 4:30087.
   PubMed Web of Science ®Google Scholar
• Li H, Pan GF, Jiang ZZ, et al. (May 2015). Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway . Acta Pharmacol Sin 36:606–13.
   PubMed Web of Science ®Google Scholar
• Li XJ, Jiang ZZ, Zhang LY. (2014). Triptolide: progress on research in pharmacodynamics and toxicology. J Ethnopharmacol 155:67–79.
   PubMed Web of Science ®Google Scholar
• Li Y-J, Wu J-Y, Hu X-B, et al. (2019). Autologous cancer cell-derived extracellular vesicles as drug-delivery systems: a systematic review of preclinical and clinical findings and translational implications. Nanomedicine (Lond) 14:493–509.
   PubMed Web of Science ®Google Scholar
• Li YJ, Wu JY, Hu XB, et al. (2019). Autologous cancer cell-derived extracellular vesicles as drug-delivery systems: a systematic review of preclinical and clinical findings and translational implications. Nanomedicine (Lond) 14:493–509.
   PubMed Web of Science ®Google Scholar
• Li YJ, Wu JY, Hu XB, et al. (2021). Biomimetic liposome with surface-bound elastase for enhanced tumor penetration and chemo-immumotherapy. Adv Healthc Mater e2100794. doi: 10.1002/adhm.202100794.
   PubMed Web of Science ®Google Scholar
• Li YJ, Wu JY, Wang JM, et al. (2020). Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer. Acta Biomater 101:519–30.
   PubMed Web of Science ®Google Scholar
• Lim JH, Jono H, Koga T, et al. (2007). Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One 2:e1032.
   PubMed Web of Science ®Google Scholar
• MacKenzie TN, Mujumdar N, Banerjee S, et al. (2013). Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol Cancer Ther 12:1266–75.
   PubMed Web of Science ®Google Scholar
• Noel P, Von Hoff DD, Saluja AK, et al. (2019). Triptolide and its derivatives as cancer therapies. Trends Pharmacol Sci 40:327–41.
   PubMed Web of Science ®Google Scholar
• Phillips PA, Dudeja V, McCarroll JA, et al. (2007). Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 67:9407–16.
   PubMed Web of Science ®Google Scholar
• Rao S, Cronin SJF, Sigl V, Penninger JM. (2018). RANKL and RANK: from mammalian physiology to cancer treatment. Trends Cell Biol 28:213–23.
   PubMed Web of Science ®Google Scholar
• Ren Q, Li M, Deng Y, et al. (2021). Triptolide delivery: nanotechnology-based carrier systems to enhance efficacy and limit toxicity. Pharmacol Res 165:105377.
   PubMed Web of Science ®Google Scholar
• Saari H, Lázaro-Ibáñez E, Viitala T, et al. (2015). Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release 220:727–37.
   PubMed Web of Science ®Google Scholar
• Shao J, Zaro J, Shen Y. (2020). Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate. Int J Nanomed 15:9355–71.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. (2021). Cancer Statistics, 2021. CA A Cancer J Clin 71:7–33.
   PubMed Web of Science ®Google Scholar
• Su Z, Yang Z, Xu Y, et al. (2015). Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer 14:48.
   PubMed Web of Science ®Google Scholar
• Sun SC. (2010). CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 17:25–34.
   PubMed Web of Science ®Google Scholar
• Villa A, Garofalo M, Crescenti D, et al. (2021). Transplantation of autologous extracellular vesicles for cancer-specific targeting. Research Paper. Theranostics 11:2034–47.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang B, Yang X. (2020). The study of cellular mechanism of triptolide in the treatment of cancer, bone loss and cardiovascular disease and triptolide's toxicity. Curr Stem Cell Res Ther 15:18–23.
   PubMed Web of Science ®Google Scholar
• Wu H, Wang MD, Liang L, et al. (2021). Nanotechnology for hepatocellular carcinoma: from surveillance, diagnosis to management. Small 17:e2005236.
   PubMed Web of Science ®Google Scholar
• Xu L, Qiu Y, Xu H, et al. (2013). Acute and subacute toxicity studies on triptolide and triptolide-loaded polymeric micelles following intravenous administration in rodents. Food Chem Toxicol 57:371–9.
   PubMed Web of Science ®Google Scholar
• Yu D, Liu Y, Zhou Y, et al. (2020). Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Proc Natl Acad Sci USA 117:9964–72.
   PubMed Web of Science ®Google Scholar
• Yurkin ST, Wang Z. (2017). Cell membrane-derived nanoparticles: emerging clinical opportunities for targeted drug delivery. Nanomedicine 12:2007–19.
   PubMed Web of Science ®Google Scholar
• Zhang KL, Wang YJ, Sun J, et al. (2019). Artificial chimeric exosomes for anti-phagocytosis and targeted cancer therapy. Chem Sci 10:1555–61.
   PubMed Web of Science ®Google Scholar